After re-reading the announcements I saw that despite there not...

After re-reading the announcements I saw that despite there not being a reference like EAP 276, patients appear to have been treated using the improved process right up to (including 2023): "Mesoblast presented consistently high survival in patients treated in RYONCIL, in children with SR-aGVHD in the EAP between 2008-2015, in the Phase 3 trial MSB-GVHD001 between 2015-2018, and in the Emergency Investigational New Drug (EIND) protocol from 2015-2023."

2015-2023 and therefore after GVHD-001/002, after CRL #1 and also after CRL #2.

----------
Ok. Still reading. Which announcement did you get the quote from? If there was only a few I'd check without asking but there are quite a few it could be in in 2023 and 2024 referring to a "protocol from 2015-2023".

BTW. Bazsa is still asking about the 11 data points. Part of me wants to show him my sources because why not be nice the other part of me says you've told him several times already he never gets it, doesn't check sources and it would be a lot more efficient from a communication point of view to simply not reply to him and so reduce the chances of him reporting me because he takes issue with a tone of frustration or something.

On one hand I think with a very large amount of time I might be able to convince even Bazsa - but it will take a long time potentially as he'll explore ever possible way of misinterpreting what I say I suspect.

Are you clear how I got down to 11 data points? Can you remember my sources (serum samples from Kasikis et al (25), statement from Silviu at ODAC specifically mentions patients) - but if you aren't perhaps its worth me doing a refresher so others perhaps besides Bazsa can see I'm not pulling stuff out of my proverbial. Bazsa thinks 40 is reasonable - that's not unreasonable for him to think that its just ignorant because he hasn't integrated the sources I have to cut that number down from 40 in my opinion - and others won't have done that either.